What are the recommendations for using mirabegron (Myrbetriq) in children with overactive bladder?

Recommendation for Mirabegron Use in Children

Mirabegron can be used as medical therapy for children aged 3 years and older with daytime lower urinary tract (LUT) conditions, though it remains off-label for idiopathic overactive bladder and is FDA-approved only for neurogenic detrusor overactivity (NDO) in children weighing ≥35 kg. 1, 2

Treatment Algorithm for Pediatric Overactive Bladder

First-Line Approach

• Start with standard urotherapy (behavioral modification, timed voiding, fluid management) for all children with daytime LUT conditions 1
• If inadequate response, add specific urotherapy interventions (biofeedback, pelvic floor exercises, alarm therapy) 1

Second-Line Medical Therapy

• Anticholinergics remain the mainstay: Oxybutynin is most commonly used as first-line pharmacotherapy 1
• Mirabegron as alternative or add-on: Consider when:
  • Child is refractory to anticholinergics after adequate trial
  • Intolerable side effects from anticholinergics (dry mouth, constipation)
  • Need for combination therapy with anticholinergics 1

FDA-Approved Indications vs. Off-Label Use

FDA-Approved (On-Label)

• Neurogenic detrusor overactivity (NDO) in children ≥3 years old:
  • Tablets: For children weighing ≥35 kg (77 lbs) 2
  • Granules: For children ≥3 years old (any weight) 2

Off-Label Use

• Idiopathic overactive bladder: Despite confirmed effectiveness and safety in multiple studies, mirabegron remains off-label for this indication 1

Dosing and Administration

For Tablets

• Take with food (pediatric patients) 2
• Swallow whole with water—do not chew, divide, or crush 2
• Typical pediatric dose: 25-50 mg once daily based on clinical studies 3, 4, 5

For Granules (Extended-Release Oral Suspension)

• Take with food within 1 hour after preparation 2
• Do not save dose for later use 2
• Shake bottle vigorously for 1 minute before each use 2

Evidence Supporting Pediatric Use

The 2025 European Association of Urology-European Society of Paediatric Urology guidelines explicitly state that effectiveness and safety of mirabegron has been confirmed in several studies for children with daytime LUT conditions. 1

Key Clinical Evidence

• Combination therapy: Mirabegron as add-on to anticholinergics showed 76% complete/partial response rate in therapy-resistant OAB 6
• Monotherapy comparison: Mirabegron demonstrated comparable efficacy to solifenacin with fewer side effects (2.8% vs 10% dry mouth, 2.8% vs 11.4% constipation) 4
• Neurogenic bladder: Increased bladder capacity by 125 mL and decreased end-filling detrusor pressure by 12 cm H₂O 7
• Continence outcomes: 72% of incontinent patients achieved dryness with mirabegron add-on therapy 3

Safety Monitoring Requirements

Mandatory Monitoring

• Blood pressure: Periodically monitor, especially in hypertensive patients—mirabegron can increase BP in adults and children 2
• Post-void residual: Check for urinary retention, particularly in patients with bladder outlet obstruction 2
• Liver function: Monitor transaminases if hepatic impairment present 2

Common Pitfalls to Avoid

• Do NOT use in severe uncontrolled hypertension 2
• Watch for angioedema: Rare but potentially life-threatening—discontinue immediately if facial/laryngeal swelling occurs 2
• Avoid crushing tablets: This destroys the extended-release formulation 2
• Missing doses: If >12 hours since missed dose, skip it and resume regular schedule 2

Clinical Positioning

Mirabegron serves three key roles in pediatric practice:

1. Alternative to anticholinergics when side effects (dry mouth, constipation, cognitive effects) are intolerable 4, 5

2. Add-on therapy for anticholinergic-refractory cases—combination therapy with low-dose anticholinergics often superior to high-dose monotherapy 3, 6

3. Exit strategy after botulinum toxin: Crucial role in managing recurring symptoms when BoNT-A effects wear off 6

Quality of Life Considerations

Symptoms of incontinence significantly impact QoL for both patients and caregivers. 1 Mirabegron improved Patient Perception of Bladder Condition scores from median 4.0 to 2.0, with 85% of patients showing complete or partial response 5. The improved tolerability profile compared to anticholinergics (17% side effects vs higher rates with antimuscarinics) supports better medication adherence and sustained QoL improvements 6, 5.

Drug Interactions

Important interactions requiring dose adjustment or monitoring: 2

• Thioridazine, flecainide, propafenone (CYP2D6 substrates)
• Digoxin (P-glycoprotein substrate)
• Solifenacin (when used in combination)

Transition Planning

Children treated for LUT conditions are more likely to have urinary symptoms in adulthood—ensure adequate transition to adult urology when needed 1. This underscores the importance of achieving optimal symptom control during childhood to potentially reduce long-term morbidity.